Anavex Life Sciences Corp (AVXL)

[falconer66a]

Another Anavex Success

Well, Anavex gets a patent for blarcamesine as a hypertension (high blood pressure) therapy. Who could have imagined it?

Me, actually. Not at all unexpected, given the drug’s ability to safely modulate and restore a wide variety of homeostatic processes, both in cells themselves, and in tissues and organ systems. There will be more revelations of a similar nature in the future. Anavex knows more than most can imagine about their unique new candidate drugs.

Two key points. First, unlike most drugs blarcamesine acts at the top, at the start, “upstream” of cell, tissue, and organ-level processes that can be disrupted to cause disease.

Secondly, do you suppose blood pressure readings have been taken rather frequently in the hundreds of patients in clinical trials involving blarcamesine? The office nurse takes your blood pressure every time you stop in your general practitioner’s office. Simply, blood pressures are taken universally in medicine, surely in clinical trials of new or candidate drugs.

Consequently, Anavex has copious records of how blood pressure was affected when blarcamesine was taken.

Then, of course, is the absolute safety of the drug. Not a single case of drug-induced mortality or severe side effects.

The potential market size for a safe, successful hypertension drug in the US is, shall we say, large.